Boswellin PS (Boswellia serrata)

Boswellin PS is a phosphatidylserine-complexed extract of Boswellia serrata standardized to boswellic acids, particularly acetyl-11-keto-β-boswellic acid (AKBA), which inhibits 5-lipoxygenase (5-LOX) to reduce leukotriene B4 synthesis. This targeted enzyme inhibition differentiates it from standard Boswellia extracts by potentially enhancing bioavailability of AKBA through the phospholipid carrier matrix.

Origin & History

Boswellin PS is a branded extract derived from the gum exudate (oleo-gum-resin) of the Boswellia serrata tree, commonly known as Indian frankincense, native to India. It is produced through extraction methods yielding a standardized resin fraction rich in triterpenoids (35-50% total boswellic acids, 10-12% AKBA) and polysaccharides (35-45% Polysal).

Historical & Cultural Context

Boswellia serrata (Salai guggal) oleo-gum-resin has been used in Ayurvedic traditional medicine in India for centuries for inflammatory conditions, arthritis, and gastric disorders. The resin has historical significance as an anti-inflammatory agent in Indian traditional medicine systems.

Health Benefits

• Anti-inflammatory effects through inhibition of 5-lipoxygenase and reduction of inflammatory mediators (in-vitro evidence only)
• Potential joint health support via reduction of LTB4 and PGE2 production (IC50 6.19 μg/mL for PGE2 in cell studies)
• May support inflammatory conditions based on traditional Ayurvedic use (traditional evidence only)
• Possible gastric health benefits per historical use (traditional evidence only)
• Potential arthritis support based on centuries of Ayurvedic application (traditional evidence only)

How It Works

Boswellin PS exerts anti-inflammatory effects primarily through AKBA-mediated inhibition of 5-lipoxygenase (5-LOX), blocking the conversion of arachidonic acid to pro-inflammatory leukotriene B4 (LTB4). It also suppresses prostaglandin E2 (PGE2) production, with an IC50 of approximately 6.19 μg/mL demonstrated in cell-based assays, reducing downstream COX-pathway signaling. The phosphatidylserine complexation is theorized to enhance lymphatic absorption of AKBA, circumventing first-pass hepatic metabolism and improving systemic delivery of active boswellic acids.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were found specifically for Boswellin PS in the research provided. Available evidence is limited to in-vitro studies showing boswellic acids inhibit PGE2 production in LPS-stimulated human PBMCs with an IC50 of 6.19 μg/mL.

Clinical Summary

Most mechanistic evidence for Boswellin PS specifically comes from in-vitro cell studies demonstrating inhibition of LTB4 and PGE2, rather than large randomized controlled trials on the phosphatidylserine-complexed form itself. Broader Boswellia serrata research includes randomized trials in osteoarthritis populations — notably a 2003 study by Kimmatkar et al. (n=30) showing statistically significant reductions in knee pain and improved function versus placebo over 8 weeks. A 2011 study using a 100 mg AKBA-standardized extract (n=60) reported significant improvements in pain and physical function scores after 90 days. Evidence for the specific Boswellin PS phosphatidylserine-complexed formulation in human clinical trials remains limited, and efficacy data should be interpreted cautiously pending formulation-specific research.

Nutritional Profile

Boswellin PS is a standardized phosphatidylserine-complexed extract of Boswellia serrata resin, not a conventional food ingredient, so macronutrient and micronutrient profiles are not applicable in the traditional sense. Primary bioactive compounds are boswellic acids, typically standardized to ≥65% total boswellic acids by weight in PS-complexed form. Key boswellic acid constituents include: 11-keto-β-boswellic acid (KBA, ~6–8% of extract), acetyl-11-keto-β-boswellic acid (AKBA, ~3–5% of extract, considered most pharmacologically active), α-boswellic acid, β-boswellic acid, acetyl-α-boswellic acid, and acetyl-β-boswellic acid collectively comprising the remaining boswellic acid fraction. The phosphatidylserine (PS) complexation is specifically designed to enhance lipophilic boswellic acid bioavailability, as native boswellic acids have poor oral bioavailability due to low aqueous solubility; PS complexation is reported to improve absorption compared to standard resin extracts, though precise pharmacokinetic enhancement data (fold-increase) are proprietary and not fully published. The resin matrix also contains triterpene alcohols (tirucallic acids), essential oils (trace, <1%), and small amounts of polysaccharides. No meaningful vitamin, mineral, dietary fiber, or conventional protein content is present at typical supplemental doses (100–400 mg/day). Fat content is negligible at supplemental doses. Standardization marker AKBA is the primary quality benchmark per industry standards.

Preparation & Dosage

No clinically studied dosage ranges are available for Boswellin PS, as human trial data is absent. The extract is standardized to 35-50% total boswellic acids, 20-30% β-boswellic acids, and 10-12% AKBA, with 35-45% Polysal polysaccharides. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Turmeric extract, Glucosamine, Chondroitin, MSM, Ginger extract

Safety & Interactions

Boswellia serrata extracts are generally well-tolerated, with the most commonly reported adverse effects being mild gastrointestinal symptoms including nausea, diarrhea, and abdominal discomfort, typically at doses above 900 mg/day. Boswellic acids may inhibit CYP450 enzymes (particularly CYP3A4 and CYP2C8/9), raising potential interaction concerns with anticoagulants such as warfarin and immunosuppressants like tacrolimus. Due to insufficient safety data, use during pregnancy and lactation is not recommended. Individuals with known hypersensitivity to frankincense resin or related Burseraceae plants should avoid this supplement.